Endonovo Therapeutics, Inc.
ENDV · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $176 | $220 | $218 | $0 |
| - Cash | $0 | $0 | $0 | -$0 |
| + Debt | $6,896 | $6,870 | $6,870 | $7,016 |
| Enterprise Value | $7,071 | $7,089 | $7,087 | $7,017 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | -$133 | -$162 |
| % Margin | – | – | – | – |
| EBITDA | -$249 | -$224 | -$227 | -$226 |
| % Margin | – | – | – | – |
| Net Income | -$558 | -$533 | -$669 | -$697 |
| % Margin | – | – | – | – |
| EPS Diluted | 0 | -0.001 | -0.001 | -0.001 |
| % Growth | 100% | 58.3% | -20% | – |
| Operating Cash Flow | – | – | $103 | -$1 |
| Capital Expenditures | – | – | -$0 | $0 |
| Free Cash Flow | – | – | $103 | -$1 |